Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Myelodysplastic Syndromes 1Melanoma 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Solid Tumors 1Advanced Solid Tumor 1

Interventions

Injections 25Carboplatin 17Docetaxel 14pembrolizumab 12Paclitaxel 11Bevacizumab 9durvalumab 8Cisplatin 8Nivolumab 6Fluorouracil 6trifluridine tipiracil drug combination 5tislelizumab 5linifanib 5Pemetrexed 5Oxaliplatin 5Leucovorin 5zimberelimab 4toripalimab 4talazoparib 4olaparib 4Itraconazole 4Irinotecan 4Gemcitabine 4Capecitabine 4tremelimumab 3sotorasib 3sintilimab 3fludarabine 3depatuxizumab 3atezolizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Solid Tumors × ulixertinib × Clear all
NCT01781429 2020-03-20

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

BioMed Valley Discoveries, Inc

Phase 1/2 Completed
136 enrolled 25 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡